- Home
- PRAX vs PHI Comparison
PRAX vs PHI Comparison
Compare PRAX & PHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | PHI |
|---|---|---|
| Founded | 2015 | 1928 |
| Country | United States | Philippines |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 4.7B |
| IPO Year | 2020 | 1953 |
Fundamental Metrics
Financial Performance| Metric | PRAX | PHI |
|---|---|---|
| Price | $286.98 | $21.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 1 |
| Target Price | ★ $373.79 | N/A |
| AVG Volume (30 Days) | ★ 771.9K | 49.6K |
| Earning Date | 11-05-2025 | 11-11-2025 |
| Dividend Yield | N/A | ★ 5.53% |
| EPS Growth | N/A | ★ 9.36 |
| EPS | N/A | ★ 2.32 |
| Revenue | $7,463,000.00 | ★ $3,761,997,877.00 |
| Revenue This Year | N/A | $2.70 |
| Revenue Next Year | $12,467.71 | $2.64 |
| P/E Ratio | ★ N/A | $9.22 |
| Revenue Growth | ★ 364.98 | 1.69 |
| 52 Week Low | $26.70 | $18.61 |
| 52 Week High | $317.72 | $25.12 |
Technical Indicators
Market Signals| Indicator | PRAX | PHI |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 57.06 |
| Support Level | $285.95 | $21.50 |
| Resistance Level | $317.72 | $22.16 |
| Average True Range (ATR) | 12.78 | 0.34 |
| MACD | -1.09 | -0.04 |
| Stochastic Oscillator | 43.76 | 66.96 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.